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Background: Studies that compare neuropsychological functioning in inpatients with mood disorder or
schizophrenia come to heterogeneous results. This study aims at investigating the question whether there are
different neuropsychological test profiles in stabilised post-acute inpatients with affective disorders or schizophrenia.
Method: We were interested in evaluating impairment in specific areas of cognitive functioning in patients with
schizophrenia or depression. In clinical reality, patients with depression and schizophrenia are often treated
together with little attention to their specific needs. 74 patients with major depression and 38 patients with
schizophrenia were assessed in a comprehensive neuropsychological battery. All patients were in a post-acute
stage of their illness, i.e. remission of acute symptoms.
Results: In spite of a comparable mean score of psychopathological symptoms in the Brief Psychiatric Rating
Scale-Expanded (BPRS-E) as well as in the Global Assessment Functioning Scale (GAF), patients with depressive
disorder showed significantly better results in verbal and visual short-term memory, verbal fluency, visual-motor
coordination, information processing in visual-verbal functioning and selective attention compared to patients with
schizophrenia. No significant differences between both samples were found in practical reasoning, general verbal
abstraction, spatial-figural functioning, speed of cognitive processing.
Conclusions: These results show that there are differences in scores in psychopathology (BPRS-E, GAF) in patients
with affective disorders or schizophrenia and different neuropsychological test profiles in the post-acute stage of
their illness.
Keywords: Neuropsychological functioning, Depressive disorder, Schizophrenia, Psychopathology, Post-acute stage
of the illnessBackground
Impaired neuropsychological functioning in schizophrenia
has been evaluated in range of meta-analyses focusing
on schizophrenia (Heinrichs and Zakzanis [1], schizo-
phrenia or bipolar disorder (Krabbendam et al. [2], and
first-episode schizophrenia (Mesholam-Gately et al. [3].
Heinrichs and Zakzanis's [1] seminal meta-analysis of
predominantly chronic schizophrenia samples showed
moderate to large effect sizes (d > .60) for all 22 neu-
rocognitive test variables. The results indicated that
schizophrenia is characterized by broad-based cognitive
impairment, with varying degrees of deficit across all
ability domains measured by standard clinical tests.* Correspondence: annette.schaub@med.uni-muenchen.de
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reproduction in any medium, provided the orKrabbendam et al. [2] analysed 31 studies and demon-
strated that patients with bipolar disorder show better
cognitive performance than schizophrenia. Mesholam-
Gately et al. [3] focused their meta-analysis on 47 studies
of first-episode schizophrenia. They found that impair-
ments are reliably present across the range of cognitive
domains, and are comparable to the degree of impair-
ment present in patients with a well-established illness;
the most pronounced impairments were in immediate
verbal memory and processing speed.
The considerable heterogeneity of effect sizes across
studies, however, underscores the variability in the im-
pact of the illness on cognitive functioning. Studies of
neuropsychological functioning comparing acutely de-
pressed patients to those with schizophrenia show simi-
larly heterogeneous results (Albus et al. [4]. PatientsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mal and schizophrenia groups, with considerable over-
lap with normal, and unknown and/or controversial
overlap with schizophrenia.
Albus et al. [4] compared patients with a first episode
of either schizophrenia or major depression and found
that depressed patients performed better in visual-motor
and attentional functioning. Mood disorder patients with-
out psychotic features did not perform significantly dif-
ferently from healthy normal controls, although those
with psychotic features performed as poorly as those with
schizophrenia. Albus et al. [5] reassessed the same patients
with first-episode schizophrenia, chronic schizophrenia,
and healthy controls again after five years and concluded
that neuropsychological impairment had already been
present at the onset of the illness and remained stable
over the early course of schizophrenia. When controlling
for relevant confounding variables, neuroleptics showed
a deleterious influence only on verbal fluency, but no other
measures of neuropsychological performance. Table 1 pro-
vides an overview of studies related to neuropsychological
differences between schizophrenia and depression.
Franke et al. [6] compared neuropsychological function-
ing in acute patients with schizophrenia or nonpsychotic
major depression, who were not currently receiving me-
dication, to healthy controls. They found only small differ-
ences in executive functions, verbal fluency, and focused
attention between patients with depression or schizophre-
nia. Mitrushina’s study [7] showed that patients with an
acute psychotic episode had significantly lower scores
in memory functioning and in reasoning than patients
with depression. Verdoux and Liraud [8] also found that
patients with schizophrenia had poorer memory func-
tioning than those with depression, although there were
no differences in executive functioning performance.
Egeland et al. [9] found that depressed patients showed
significantly better performance in working and declara-
tive memory than schizophrenia patients. Reichenberg
et al. [10] investigated neuropsychological functioning
in schizophrenia and mood disorder two years after
index hospital admission. Both groups had impairments
in memory, executive functioning, attention and pro-
cessing speed; however, patients with schizophrenia
were more impaired across all cognitive domains. Im-
pairment in neuropsychological performance is com-
mon in people with major depression with psychotic
features. However, as in schizophrenia, a minority of
these individuals perform within the normal range, with
estimates of the prevalence of normal psychological
functioning ranging between 42% and 77% in major de-
pression, compared to 16% to 45% in schizophrenia.
This study investigated whether there were significant
neuropsychological differences between post-acute inpa-
tients with major depression compared to those withschizophrenia. In addition, the relationships between symp-
toms and neurocognitive performance were evaluated.
Methods
Setting and sample
The study was conducted with inpatients in the Depart-
ment of Psychiatry and Psychotherapy, Ludwig Maximilian
University of Munich. After receiving permission of the
ethical committee, all potentially eligible patients were
approached to participate in the study. A total of 112
patients provided signed informed consent and were
included in the study, which began in February 1998
and ended in November 2000. Inclusion criteria were:
ICD-10 diagnosis of schizophrenia or major depression;
hospitalized for treatment of an acute episode of the ill-
ness; and sufficient symptom stabilization to permit
participation in the neuropsychological evaluation. All
patients were treated with psychopharmacological in-
terventions.
Thirty-eight patients had schizophrenia (17 women, 21
men) and 74 had major depression (38 women, 36 men),
a similar gender distribution for these diagnoses to that
seen in this hospital. Table 2 summarizes the diagnoses
of the sample and Table 3 describes their demographic
and clinical characteristics.
Instruments
Diagnoses were made according to ICD-10 criteria and
drawn from charts. Symptoms were assessed with the
Brief Psychiatric Rating Scale Expanded (BPRS-E [11]),
the Global Assessment of Functioning Scale (GAF, [12],
the Scale for the Assessment of Negative Symptoms
(SANS [13], Munich version [14], the Hamilton Depres-
sion Scale (HAMD, [15], and the Montgomery Asberg
Depression Rating Scale (MADRS, [16]. The factors for
the BPRS-E were based on those from Velligan’s [17]
factor analysis, including: depression/anxiety, activation,
retardation and psychosis.
All participants were also evaluated with a comprehen-
sive neuropsychological battery. Consistent with previous
studies of neuropsychological functioning in schizophrenia
and mood disorders [1-11] the individual measures ad-
ministered to all subjects were selected to assess verbal
intelligence, fluency, visual-figural problem solving, simple
and focused attention as well as verbal learning and
memory. The instruments included the German Version
of the Auditory Verbal Learning Memory Test (VLMT,
Helmstedter et al. [18], Word fluency Test from Regens-
burg (RWT; Aschenbrenner et al. [19], Visual test I and II
from the Wechsler Scale [20], Subscales of the German
Wechsler Adult Test Revised (WAIS-R) [21]: Information,
Similarities, Picture Completion, Block Design, Digit sym-
bol test and the German version of the Colour Word
Interference test (STROOP; Bäumler [22].
Table 1 Overview of studies related to neuropsychological differences in schizophrenia or depression
Author Franke et al. (1993)
[6]




Reichenberg et al. (2008)
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Digit Span Test (DST)
Wechsler Adult Intelligence Scale
(WAIS-R), WCST, Verbal fluency
Test, Wechsler Memory Scale
(WMS-R), California Verbal Learning
Test, TMT, Stroop Test, Continous
Performance Test, Span of
Apprehension Test
Neurobehavioral Cognitive Status
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Facial Recognition Test,
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Repetition Test
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without psychotic symptoms = Cont
A with psychotic symptoms = S
Memory, abstract thinking: distinct
deficits in patients with
schizophrenia (S < D)
Global memory
functioning: S < D; verbal
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D < S
S < SA < B < D
< = “worse than”.

















Table 2 Distribution of diagnosis (ICD-10) post-acute
inpatients with depression (n = 74) or schizophrenia
(n = 38)
Depressive disorder
Moderate or minor depression 1 (1.4%)
Remitted 1 (1.4%)
Minor depressive episode 2 (2.7%)
Moderate depressive episode 14 (19%)
Severe depressive episode without psychotic symptoms 19 (25.7%)
Severe depressive episode with psychotic symptoms 6 (8.1%)
Moderate episode 6 (8.1%)
Moderate episode without psychotic symptoms 10 (13.5%)
Severe depressive episode with psychotic symptoms
within a recurrent disorder 3 (4.1%)
unknown 12 (16.2%)
Schizophrenia
Paranoid schizophrenia 21 (55.3%)
Hebephrene schizophrenia 3 (7.9%)
Catatone schizophrenia 1 (2.6%)
Undifferentiated schizophrenia 3 (7.9%)
Schizophrenia simplex 1 (2.6%)
Delusional disorder 2 (5.3%)
Acute polymorphe psychotic disorder 3 (7.9%)
Acute polymorphe psychotic disorder with schizophrenia 1 (2.6%)
Acute schizophreniform psychotic disorder 2 (5.3%)
Schizophrenic disorder at present manic 1 (2.6%)
Table 3 Chi-square tests comparing patients with major
depression (n = 74) and schizophrenia (n = 38) on




Schizophrenia Chi-Square df Signif.
Sex:
Women 38 (51.4%) 17 (44.7%) .440 1 .507




22 (31.4%) 24 (63.2%) 10.14 1 .001




26 (37.1%) 18 (47.4%) 1.07 1 .302
Higher
education
44 (62.9%) 20 (52.6%)
Work
qualification:
Unskilled 16 (23.2%) 13 (34.2%) 1.51 1 .220
Skilled worker 53 (76.8%) 25 (65.8%)
Employment
status:
Unemployed 26 (37.1%) 17 (44.7%) .593 1 .441




50 (72.5%) 36 (94.7%) 7.71 1 .006
Multiple
admission
19 (27.5%) 2 (5.3%)
*The boldface data are to mark the significance of the data: p*<05;
p**<0.01; p***<0.001.
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lected for analysis in this study based on the availability
of comprehensive norms, including VLMT, RWT, Visual
test, WAIS-R and STROOP. The symptom assessments
and neuropsychological tests were administered by psy-
chologists with experience in evaluating patients with se-
vere mental illness.
Data analysis
Chi-square tests were conducted to compare patients
with major depression and schizophrenia on categorical
demographic variables and history of hospitalization
(first episode vs. multiple episode). Analyses of variance
(ANOVAS) were performed to compare the two groups
on continuous demographic variables and the symptom
measures. The patients with major depression were
significantly older than those with schizophrenia. To
statistically adjust for the potential effects of age on the
comparisons of the groups on the cognitive measures,
analyses of covariance (ANCOVAS) were performed,
including age as a covariate.
There are over 30 dependent variables and therefore
we did a (Bonferonni) correction for multiple analyses(.05/30 = .00167). Therefore, effects significant at p < .002
were considered statistically significant, whereas ef-
fects significant a the conventional p < .05 but not the
Bonferroni corrected level were considered trends.
Results
Demographic and clinical data
In addition to being older, the patients with depression
and schizophrenia differed significantly in marital status
and history of prior hospitalisations. Depressed patients
were more likely to have been married and to have had
prior hospitalizations than patients with schizophrenia.
There were no significant differences in age at onset,
duration of illness, education, total duration of inpatient
treatment or total scores in BPRS-E and in GAF. How-
ever, there were significant differences in several of the
BPRS-E subscales. Depressed patients had significantly
worse scores on the subscales depression, anxiety, sui-
cidality and hostility, and significantly less severe scores
Table 4 One-way ANOVAS focusing on continuous
demographic variables and symptoms (F2-Diagnosis:
n = 38, F3-Diagnosis: n = 74)
Variable Diagnoses M SD df F Significance
Age F2 33.50 12.14 (1,110) 9.826 .002
F3 41.07 12.08












F2 5.32 2.11 (1,105) 2.885 .092
F3 8.16 10.18
GAF F2 55.08 12.86 (1,101) .234 .630
F3 53.95 10.33
BPRS F2 37.00 6.82 (1,100) .268 .606
F3 37.75 7.22
Anxiety F2 2.18 1.04 (1,100) 15.24 .000
F3 3.19 1.37
Depression F2 1.68 .96 (1,100) 32.43 .000
F3 3.14 1.39
Suicidality F2 1.16 .72 (1,100) 6.05 .016
F3 1.64 1.07
Hostility F2 1.05 .32 (1,100) 12.83 .001
F3 1.39 .79
Grandiosity F2 1.39 1.00 (1,100) 6.88 .010
F3 1.05 .28
Suspiciousness F2 2.21 1.09 (1,100) 12.83 .001
F3 1.56 .73












F2 1.26 .60 (1,100) 4.15 .044
F3 1.06 .39
SANS(F2) F2 29.89 20.61
Single score
SANS (F2) F2 6.97 4.75
Total score
MADRS (F3) F3 19.04 7.85
HAMD (F3) F3 17.28 6.99
*The boldface data are to mark the significance of the data: p*<05;
p**<0.01; p***<0.001.
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nations, unusual thought, bizarre behaviour, grandiosity
and conceptual disorganisation than patients with schizo-
phrenia. Table 4 summarizes the results.
Neuropsychological functioning
The results of the ANCOVAs comparing cognitive per-
formance in the patients with depression with schizophre-
nia are summarized in Table 5. Patients with depression
had significantly better cognitive performance than those
with schizophrenia on the following variables: VLMT;
immediate recall of words, verbal learning, free recall,
both subtests of verbal fluency (RWT) (letters and;
categories); the Visual test and Digit symbol coding on
the HAWIE, as well as two sub-items of STROOP. The
remaining variables showed no significant differences




The results of this study found differences in neuro-
psychological functioning between patients with depres-
sion and patients with schizophrenia in the post-acute
stage of their illness. Similar differences have been re-
ported in several previous studies. In spite of comparable
total scores in BPRS-R and GAF, patients with post-
acute depression show significantly better results in sev-
eral cognitive assessments (verbal memory and fluency,
visual-motor concentration, information processing in
visual-verbal areas and selective attention) compared to
their counterparts. Special attention should be paid to
the following result: Patients with depression were sig-
nificantly older and had a significantly higher number of
hospitalizations. These aspects might indicate a more se-
vere course of the illness and hint at worse performing
in neuropsychological functioning. However, there were
no significant differences in other cognitive variables such
as verbal comprehensiveness, reasoning, spatial perception
and visual abstract processing, cognitive processing, and
abstract cognitive reasoning.
Comparison to other studies
Comparing the results of this study with other studies
the following conclusions can be drawn. Many studies
[3-10] show better performance in patients with depres-
sion than in patients with schizophrenia. Comparing our
study with the results of Reichenberg [10] shows similar-
ities to Albus et al. [3]: patients with schizophrenia show
the lowest level of neuropsychological functioning com-
pared to depression and bipolar disorder, however,
psychotic features turn out to be the most important
characteristics.
Table 5 Oneway ANCOVAS focusing on neuropsychological
tests (F2-Diagnosis: n = 38, F3-Diagnosis: n = 74) with age
as covariate
Variable Diagnoses M SD F Significance
VLMT F2 5.68 1.96 11.20 .001
Immediate memory F3 6.58 1.88
VLMT F2 47.42 10.80 8.83 .004
Learning (1–5) F3 50.16 10.41
VLMT F2 9.21 3.27 8.71 .004
Free recall F3 10.27 3.69
VLMT F2 .9442 .0611 .045 .832
Embedded recall F3 .9277 .072
RWT F2 43.71 9.88 21.75 .000
Categories F3 53.45 12.53
RWT F2 36.29 15.83 8.65 .004
Letter F3 43.43 14.16
Visualtest F2 64.37 32.75 2.66 .106
Immediate F3 70.88 29.81
Visualtest F2 54.76 34.94 4.64 .033
Short-term F3 64.18 34.27
HAWIE F2 11.51 3.45 .388 .535
Information F3 11.69 3.33
HAWIE F2 11.78 3.74 1.44 .223
Similarities F3 12.48 3.39
HAWIE F2 9.61 4.45 2.77 .100
Picture completion F3 10.55 4.17
HAWIE F2 9.31 4.30 1.45 .232
Block design F3 9.84 3.18
HAWIE F2 8.14 2.66 12.16 .001
Digit symbol test F3 10.18 3.18
STROOP: fwl F2 44.76 7.77 16.63 .000
STROOP: fwl F3 53.17 8.38
STROOP: fsb F2 47.32 7.75 18.99 .000
STROOP: fsb F3 51.99 9.37
STROOP: T-Score F2 47.86 11.21 .575 .568
NOM F3 49.41 9.12
STROOP: T-Score F2 52.49 8.46 .000 .991
SEL F3 52.34 9.25
STROOP: Age-related F2 45.24 7.93 11.68 .001
norm fwl F3 51.62 7.93
STROOP: Age related F2 45.08 8.45 12.73 .001
norm fsb F3 52.18 9.49
STROOP: Age related- F2 47.03 8.68 12.30 .001
norm int F3 53.09 7.08
*The boldface data are to mark the significance of the data: p*<05;
p**<0.01; p***<0.001.
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Shortcomings are due to different sample sizes. There
was no matching of the patients according to age and
duration of illness to control for demographic and clin-
ical variables and their impact on the results. It should
be pointed out that this study did not include a control
group of non-psychiatric patients or healthy individuals,
however, the overall assessments measures were selected
for analysis in this study because of the availability of
comprehensive norms. The large majority of the patients
were under pharmacological treatment. In comparison
to other studies we found that the treatment with neuro-
leptics [23] improved cognitive functioning, however,
there is also some evidence that drugs with anticholiner-
gic properties may have a negative impact on memory
performance [24].
We analysed several sociodemographic and clinical attri-
butes, however, there were only significant differerences
with regard to marital status, first admission versus mul-
tiple admission recurrent, number of hospitalisations and
especially age. Future studies are to investigate whether
the given neuropsychological differences between patients
with acute schizophrenia or depression continue to persist
in the course of the illness i.e. patients with different disor-
ders recover differently from their acute episode. The
non-significant difference in the BPRS-E total score be-
tween major depression and schizophrenia does not reveal
information about the strength of the symptom cluster.
The same total score may reveal a different profile of
symptoms. We agree to the consensus that schizophrenia
is marked by cognitive impairments that do not appear to
be secondary to symptoms and point to localized brain
dysfunction. The addition of functional competence to
standard cognitive test data [25] yields a significant in-
crease in validity only for concurrent and not for longitu-
dinal prediction of community independence. The specific
real-world validity of functional competence is modest
and this information is largely redundant with standard
cognitive performance.
Implications of findings in aiding patient management
During the last 20 years illness management programmes
gained importance in the treatment of schizophrenia.
Illness management is a broad set of strategies designed
to help individuals with serious mental illness collabor-
ate with professionals in managing their mental illness,
reduce their susceptibility to the illness (e.g., relapses,
effects on functioning), cope with their symptoms, and
discover (or rediscover) their strengths and abilities for
pursuing personal goals (Mueser et al. [26]. These prog-
rammes are based on the vulnerability stress model [27]
and its further development enriched with coping and
competency [28] as well as the transtheoretical model [29]
that proposes motivation to change over a series of stages
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to help clients identify and pursue their personal goals
and to explore how improved illness management can
help them achieve these goals.
At the Department of Psychiatry and Psychotherapy,
Ludwig Maximilian University of Munich, illness manage-
ment programmes were set up since 1995 for patients
with schizophrenia [30-32] or mood disorder [33,34] in-
cluding groups for patients as well as distinct groups
for relatives adapted to the needs of acute psychiatry.
The programmes include psychoeducational elements
(e.g. handouts for important topics) and cognitive be-
havioural learning principles including building up re-
warding activities, stress management skills, cognitive
restructuring and relapse prevention. These groups are
based on sound didactic and behavioural principles as
patients in severe psychiatric illness suffer from deficits
in neuropsychological functioning that have to be com-
pensated [31,32]. Strategies include personalization of
treatment, rewarding and positive social interactions,
illustration and summarizing important information, as
well as acknowledging overstimulation (e.g. providing a
“chair to rest” without questions being asked for over-
loaded patients, however, rewarding the patient’s pres-
ence). Differences in neuropsychological functioning
between these two samples led to a shorter duration
and less demanding cognitive strategies and homework
assignments in the programme for schizophrenia com-
pared to those in mood disorder.
Cognitive therapy has recently gained prominence in
the treatment of schizophrenia with process and content
interventions being two general approaches to address
cognitive dysfunctions. Whereas process interventions
aim at remediating basic information-processing skills
that serve as vulnerability markers for further episodes
(e.g. Wykes and Spaulding [35] content approaches (e.g.,
Beck et al. [36] focus on changing the nature of or one’s
response to dysfunctional thoughts and, or unlike the
latter put more emphasis on stress management (e.g.,
Schaub et al. [30], however relatively few patient charac-
teristics were predictive of benefit from participations in
these programmes [32]. In adapting CT for low-function-
ing patients with schizophrenia, Beck and his group [36]
shifted the emphasis from the predominantly symptom-
oriented approach to a person-oriented therapeutic ap-
proach by highlighting the patients’ interests, assets, and
strengths. The objective is to improve the level of func-
tioning in the form of enhanced productivity, independ-
ence, and quantity and quality of social interactions. Beck
et al. [37] developed the framework for this therapy from
the finding that dysfunctional beliefs, in conjunction
with neurocognitive impairment, impede functioning.
Another treatment approach is largely influenced by
the principles and spirit of the Recovery Movement(Mueser et al. [26]). In a group of patients with cognitive
deficits this approach turned out to be efficient and
therefore seems promising for this group of patients as a
low level of cognitive functioning may turn out as a rate
limiting factor for therapy Mueser et al. [38]. The work
on CBT and so-called cognitive remediation is broad
and diverse, covers a range of paradigms relevant to the
findings of this study, and is beginning to reveal complex
relationships between baseline functioning and treat-
ment effects. In fact, the neuropsychological level of ana-
lysis of this study refers less to the schematic approach
of Beck than to most other CBT approaches for psych-
osis. The overview of Wykes and Spaulding [35] as well
as the study by Silverstein et al. [39] are promising in so
far as attention shaping e.g. turned out to be an effective
example of support cognition, in that cognitive abilities
are improved within the environmental context where
the patient is experiencing difficulty, leading to gains in
both attention and functional outcome.
This study refers to post- acute inpatients with low
symptom profiles that were close to remission. The low
symptom profile limits generalization as due to the new
health system with shorter inpatient stay patients are less
likely to be in such a stable state. Patients with schizo-
phrenia showed lower cognitive functioning compared to
patients with mood disorder, however, they could also
benefit from illness management programmes if these
were to compensate the patients’ cognitive deficits.
Conclusions
In summary we found that in spite of comparable total
scores in psychopathology (BPRS-E, GAF) patients with
affective disorders compared to patients with schizophre-
nia showed different neuropsychological test profiles in
the post- acute phase of their illness. Schizophrenia is
marked by cognitive impairments that do not appear
secondary to symptoms.
The different results in neurofunctioning in mood dis-
order and schizophrenia laid the foundation for different
illness management programmes in both samples that re
to compensate for neuropsychological deficits.
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